Tyler Zemla

Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial

Robert D. McBane, Waldemar E. Wysokiński, Jennifer Le‐Rademacher et al. · Journal of Thrombosis and Haemostasis · 2019 · 578 citations

Medicine, Pharmacology, Pharmacotherapy +14

Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome

Federico Innocenti, Fang‐Shu Ou, Xueping Qu et al. · Journal of Clinical Oncology · 2019 · 323 citations · Full text

Medicine, Genetics, Oncology +17

Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance)

Heinz‐Josef Lenz, Fang‐Shu Ou, Alan P. Venook et al. · Journal of Clinical Oncology · 2019 · 253 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors

Jennifer A. Chan, Susan M. Geyer, Tyler Zemla et al. · New England Journal of Medicine · 2024 · 136 citations · Full text

Medicine, Oncology, Pharmacology +9

Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer

Jeffrey A. Meyerhardt, Qian Shi, Charles S. Fuchs et al. · JAMA · 2021 · 130 citations · Full text

Medicine, Oncology, Pharmacology +16